Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS)
Health Care · Biotechnology · US
$2.94
-5.16% today · +105.3% 1Y
Acumen Pharmaceuticals, Inc. (NasdaqGS: ABOS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $224.18M and employs 61 people.
Over the last twelve months the share price has gained 105.3%, trading between 1.21 and 3.60.
Tweenvest scores Acumen Pharmaceuticals, Inc. across four factors: quality 29/100. Its strongest factor is quality.
ABOS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $224.18M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.64
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- $3.60
- 52-week low
- $1.21
- Avg volume (3M)
- —
- Shares outstanding
- 72.32M
- Employees
- 61
- Next earnings
- —
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
- ISIN
- US00509G2093
- Founded
- 1996
- Listed since
- Jul 1, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.33 | -1.30% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.88 | -0.53% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.67 | -0.07% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.00 | -0.33% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $818.88 | -1.76% |
| argenx SEENXTBR: ARGX | $64.17B | €900.00 | +2.37% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.84 | -6.92% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.